Lance Armstrong’s Era of Performance — Part II: Revisiting His Time Trial Wins

Hein F.M. Lodewijkx^1, and Arjan E.R. Bos¹

¹Faculty of Psychology and Educational Sciences, Open University of the Netherlands, Heerlen, the Netherlands

Cite this paper:
Hein F.M. Lodewijkx and Arjan E.R. Bos. Lance Armstrong’s Era of Performance — Part II: Revisiting His Time Trial Wins. American Journal of Sports Science and Medicine. 2014; 2(5):194-201. doi: 10.12691/ajssm-2-5-4

Abstract

This archival study (N = 100) compared Lance Armstrong’s time trial wins to victories demonstrated by all former multiple Grand Tour winners (1949–1995; Coppi, Anquetil, Merckx, Hinault, Indurain) and by riders who won similar races in the three major European Grand Tours (Tour de France, Giro d’Italia, and Vuelta a España) from 2006 to 2013, who were either involved in doping affairs or not. Regression analyses yielded a non–significant M = 142 seconds difference between Armstrong vs. the aggregated other riders (ΔR² = .001, p = .20). The effect emerged after controlling for the influence of competition year (b = -12.23 s per year, ΔR2 = .045, p ≤ .001) and trial distances (b = 84.64 s per kilometer trial distance, ΔR² = .933, p ≤ .001) on the variation in riders’ speed. Furthermore, Armstrong along with other riders who were suspended for doping use or who acknowledged having used doping in the 2006–2013 periods did not outperform riders who were not involved in doping affairs during the same years (M = -68 s, ΔR² = .01, p = .35). Findings disprove the argument from ignorance, a false logic which refers to the often heard opinion that cyclists’ performances over time (including Armstrong’s wins) are mainly determined by their use of increasingly potent doping aids. However, in contrast to this logic, the distances of the time trials constitute the main determinant of riders’ performances rather than the year in which they competed, and riders engaged in doping affairs did not significantly outperform riders who were not.

Keywords:
doping professional cycling time trial performance

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	A. Dilger, B. Frick and F. Tolsdorf, “Are athletes doped? Some theoretical arguments and empirical evidence”, Contemporary Economic Policy, 25 (4), 604-615, 2007.
[2]	W. Voet, Breaking the chain, London, Yellow Jersey Press / Random House, 2001.
[3]	T. Hamilton and D. Coyle, The secret race, New York, Bantam Books, 2012.
[4]	USADA, Statement from USADA CEO Travis T. Tygart regarding the U.S. Postal Service Pro Cycling Team doping conspiracy, 2012. Available http://cyclinginvestigation.usada.org
[5]	USADA, Reasoned decision of the United States Anti–Doping Agency on disqualification and ineligibility, 2012. Available http://cyclinginvestigation.usada.org
[6]	H. F.M. Lodewijkx and P. Verboon, “Lance Armstrong’s era of performance – Part I: Are his time trial performances much different from other winners?”, Journal of Athletic Enhancement, 2 (1), 2013.
[7]	T. V. Perneger, “Speed trends of major cycling races: Does slower mean cleaner?”, International Journal of Sports Medicine, 31, 261-264, 2010.
[8]	H. Vandeweghe, Who has faith in cyclists anymore? [In Dutch: Wie gelooft de coureurs nog?], Ghent (Belgium), Borgerhoff and Lamberigts, 2013.
[9]	R. T. Carroll, The skeptic's dictionary: A collection of strange beliefs, amusing deceptions, and dangerous delusions, Hoboken (NJ), John Wiley and Sons, 2003.
[10]	N. El Helou, G. Berthelot, V. Thibaut, M. Tafflet, H. Nassif, F. Campion., …J.-F. Toussaint, “Tour de France, Giro, Vuelta, and classic European races show a unique progression of road cycling speed in the last 20 years”, Journal of Sports Sciences, 28 (7), 789-796, 2010.
[11]	H. F. M. Lodewijkx, “Lance Armstrong’s era of performance – Part III: Demonstrating the post hoc fallacy”, American Journal of Sports Science and Medicine, 1 (4), 63-70, 2013.
[12]	H. F. M. Lodewijkx and B. Brouwer, “Some empirical notes on the ‘epo epidemic’ in professional cycling”, Research Quarterly for Exercise and Sport, 82 (4), 593-608, 2011.
[13]	H. F. M. Lodewijkx and B. Brouwer, “Tour, Giro, Vuelta: Rapid progress in cycling performance starts in the 1980s”, International Journal of Sports Science, 2 (3), 24-31, 2012.
[14]	WADA. World Anti-Doping Agency Prohibited list, 2013. Available http://www.wada-ama.org/en/World-Anti-Doping-Program/Sports-and-Anti-Doping-Organizations/International-Standards/Prohibited-List/.
[15]	D. Magnier, P. Picq, M. Debreilly, P. Zingoni, H. Haffreingue, and J.–L Bey, Cycling remembered. [In French: Mémoires du cyclisme], 2013. Available http://www.memoire–du–cyclisme.eu.
[16]	A. Lucia, C. Earnest and C. Arribas, “The Tour de France: a physiological review”, Scandinavian Journal of Medicine and Science in Sports, 13, 275-283, 2003.
[17]	H. F. M. Lodewijkx and P. Verboon, “The Texas sharpshooter in the three Grand Tours (1933-2013): No evidence for superior time trial performances in the epo era”, Manuscript submitted for publication, Breda (the Netherlands), Open University of the Netherlands, 2014.
[18]	A. F. Hayes, “INDIRECT: An SPSS-macro for estimating indirect path coefficients in regression models”, 2013. Available http://afhayes.com/spss-sas-and-mplus-macros-and-code.html\.
[19]	K. J. Preacher and A. F. Hayes, “Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models”, Behavior Research Methods, 40, 879-891, 2008.
[20]	B.G. Tabachnick and L.S. Fidell, Using multivariate statistics (4th ed.), Boston, Allyn and Bacon / Pearson Education Company, 2001.
[21]	H. Verbruggen, “The EPO epidemic in sport”, Bloodline Reviews, 1, 3-4, 2001.
[22]	H. Kuipers, “Putative effects of doping in cycling” [In Dutch: “Vermeende effecten van doping in de wielersport”], Nederlands Tijdschrift voor Geneeskunde, 150, 2643-2645, 2006.
[23]	C. Lundby, C. and N.V. Olsen, “Effects of recombinant human erythropoietin in normal humans”, Journal of Physiology, 589, 1265-1271, 2011.
[24]	J. R. Bytomski, C. T. Moorman III and D. MacAuley, Oxford American handbook of sports medicine, Oxford, Oxford University Press, 2010.
[25]	C. Lundby, P. Robach and B. Saltin, “The evolving science of detection of ‘blood doping’ ”, British Journal of Pharmacology, 165, 1306-1315, 2012.
[26]	H. F. M. Lodewijkx, B. Brouwer, H. Kuipers and R. van Hezewijk, “Overestimated effect of epo administration on aerobic exercise capacity: A meta–analysis”, American Journal of Sports Science and Medicine, 1 (2), 17-27, 2013.
[27]	J. A. A. C. Heuberger, J. M. Cohen–Tervaert, F. M. L. Schepers, A. D. B. Vliegenthart, J. I. Rotmans, J. Daniels … A. F. Cohen, “Erythropoietin doping in cycling: Lack of evidence for efficacy and a negative risk–benefit”, British Journal of Clinical Pharmacology, 75 (6), 1406-1421, 2013.
[28]	D. H. Catlin, C. K. Hatton and F. Lasne, Abuse of recombinant erythropoietins by athletes. In G. Moulineux, M. A. Foote and S. G. Elliott (Eds.) Erythropoietins and erythropoiesis, Basel, Birkhäuser Verlag, 2006, 205-228.
[29]	B. F. Brewer, “Commercialization in professional cycling 1950-2001: Institutional transformations and the rationalization of doping”, Sociology of Sport Journal, 19, 276-301, 2002.
[30]	W. Fotheringham, Fallen angel: The passion of Fausto Coppi, London, Yellow Jersey Press, 2009.
[31]	B. Maso, The sweat of the Gods, Norwich (UK), Mousehold Press, 2005.